Rhythm Pharmaceuticals (RYTM) Liabilities and Shareholders Equity (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Liabilities and Shareholders Equity for 11 consecutive years, with $442.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 14.39% year-over-year to $442.3 million; the TTM figure through Mar 2026 stood at $1.8 billion (up 18.22% YoY), while the FY2025 annual figure was $480.2 million, up 22.41% from the prior year.
• Liabilities and Shareholders Equity retreated to $442.3 million in Q1 2026 per RYTM's latest filing, from $480.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $506.9 million in Q3 2025 and bottomed at $258.7 million in Q1 2024.
• Historically, Liabilities and Shareholders Equity has averaged $368.4 million across 5 years, with a median of $372.7 million in 2025.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 32.54% — and 2025, when it soared 49.5%.
• Rhythm Pharmaceuticals' Liabilities and Shareholders Equity stood at $382.5 million in 2022, then decreased by 13.0% to $332.7 million in 2023, then gained by 17.89% to $392.3 million in 2024, then climbed by 22.41% to $480.2 million in 2025, then fell by 7.89% to $442.3 million in 2026.
• Business Quant data shows RYTM's Liabilities and Shareholders Equity at $442.3 million in Q1 2026, $480.2 million in Q4 2025, and $506.9 million in Q3 2025.